Evrysdi Risdiplam Tablet Is Now Approved For Broader Use In SMA

Leave a Comment / Front Page News, Industry Updates, Latest News, Uncategorized /

We’re excited to share an important update for the spinal muscular atrophy (SMA) community. The U.S. Food and Drug Administration (FDA) has approved a label expansion for Evrysdi® (risdiplam) tablets, effective February 10, 2026. The tablet formulation is now approved for administration via nasogastric (NG) or gastrostomy (G) feeding tubes after dispersion in water. This

Evrysdi Risdiplam Tablet Is Now Approved For Broader Use In SMA Read More »

Cure SMA Awards $150,000 Grant to Christian Simon, PhD, at Leipzig University in Germany

Leave a Comment / Front Page News, Our Impact, Research, Uncategorized /

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to

Cure SMA Awards $150,000 Grant to Christian Simon, PhD, at Leipzig University in Germany Read More »

Cure SMA Awards $75,000 Grant to Jiangbing Zhou, PhD, at Yale University

Leave a Comment / Front Page News, Our Impact, Research /

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to

Cure SMA Awards $75,000 Grant to Jiangbing Zhou, PhD, at Yale University Read More »

Cure SMA Awards $150,000 Grant to Emma Sutton, PhD, at Ottawa Hospital Research Institute in Canada

Leave a Comment / Front Page News, Our Impact, Research, Uncategorized /

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to

Cure SMA Awards $150,000 Grant to Emma Sutton, PhD, at Ottawa Hospital Research Institute in Canada Read More »

Cure SMA Awards $150,000 Grant to Anton Blatnik, PhD, at Case Western Reserve University

Leave a Comment / Front Page News, Latest News, Our Impact, Research /

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal muscular atrophy (SMA) biology. Our Scientific Advisory Board ranks the submitted proposals based on their scientific merit and their alignment with Cure SMA’s research priorities. Funding is then awarded to

Cure SMA Awards $150,000 Grant to Anton Blatnik, PhD, at Case Western Reserve University Read More »

Biogen Announces Results from the Phase 2/3 DEVOTE Study

Leave a Comment / Front Page News, Industry Updates, Latest News, Research /

Today, Biogen announced the publication of results from the pivotal Phase 2/3 DEVOTE study in Nature Medicine, highlighting the potential benefits of a high-dose regimen of nusinersen for people living with spinal muscular atrophy (SMA). The study evaluated a higher loading and maintenance dose regimen of nusinersen and demonstrated improvements across key areas, including motor

Biogen Announces Results from the Phase 2/3 DEVOTE Study Read More »

SMA Community Research and Legislative Priorities Finalized in New Federal Law

Leave a Comment / About SMA, Advocacy, Front Page News, Latest News /

On February 3rd, Congress approved and the President signed into law key research and legislative priorities that Cure SMA and individuals with spinal muscular atrophy (SMA) and their families have been advocating for over the past year. The Consolidated Appropriations Act of 2026 includes the following provisions that will benefit children and adults with SMA

SMA Community Research and Legislative Priorities Finalized in New Federal Law Read More »

Genentech Releases Winter SMA Community Update Letter

Leave a Comment / Front Page News, Industry Updates, Latest News /

Genentech recently released an update on their continued collaboration with the SMA community and Evrysdi® tablet updates. They will continue to provide timely updates as they become available. Read the full community update letter here. “Looking back, 2025 was a time that was undeniably defined as a year of great change. We successfully navigated shifts,

Genentech Releases Winter SMA Community Update Letter Read More »

All 2026 Walk-n-Roll Events Are Open

Leave a Comment / Events & Fundraising, Front Page News, Latest News /

Cure SMA warmly invites you to join us at one of our 2026 Walk-n-Roll events—where community meets impact! This year, you can register and start fundraising for both spring and fall events right now. Walk-n-Roll isn’t just a fundraiser; it’s a celebration of progress, hope, and togetherness. It’s a chance to gather with others who

All 2026 Walk-n-Roll Events Are Open Read More »

Scroll to Top